Idarubicin
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06928662CT.gov Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | — | Recruiting | — | — | — |
NCT04214249CT.gov BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03330821CT.gov Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03226418CT.gov Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02632708CT.gov Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | — | Active Not Recruiting | — | — | — |
NCT02115295CT.gov Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | — | Recruiting | — | — | — |
NCT01876953CT.gov Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01132586CT.gov Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00666588CT.gov Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00331513CT.gov Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT00096148CT.gov Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT00096122CT.gov Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00209833CT.gov Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Idarubicin (this asset) | Fred Hutchinson Cancer Center | P2/3 | BB · 70 |
| Nivestim | City of Hope Medical Center | P2/3 | BBB |
| Cytarabine | National Cancer Institute (NCI) | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Mitoxantrone | Institut de Recherches Internationales Servier | P2 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort
Other indications for Idarubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 81 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BBB · 76 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Idarubicin in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/idarubicin-therapy-related-acute-myeloid-leukemia-and-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →